• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Natural history of nonhuman primates after oral exposure to Ebola virus variant Makona - IDSA

Mary Wilson

Well-known member
Published: 22 June 2023​

https://doi.org/10.1093/infdis/jiad225

Abhishek N Prasad, Krystle N Agans, Joan B Geisbert, Viktoriya Borisevich, Daniel J Deer, Natalie S Dobias, Jason E Comer, Courtney Woolsey, Karla A Fenton, Thomas W Geisbert ... Show more

Abstract

Background
The primary route of infection by Ebola virus (EBOV) and other pathogenic filoviruses in humans is through contact of contaminated body fluids with mucosal surfaces. Few studies have explored infection of nonhuman primates (NHPs) via the oral mucosa, which is a probable portal of natural infection in humans.

Methods
To further characterize the pathogenesis of EBOV infection via the oral exposure route, we challenged cohorts of cynomolgus monkeys with low doses (100 PFU, 50 PFU, 10 PFU) of EBOV variant Makona to better characterize virus infection and the host immune response via this route.

Results
Infection with 100 or 50 PFU of EBOV Makona via the oral route resulted in 50% and 83% lethality, respectively. Animals that progressed to fatal disease exhibited lymphopenia, marked coagulopathy, high viral loads, and increased levels of serum markers of inflammation and hepatic/renal injury. Survival in these cohorts was associated with milder fluctuations in leukocyte populations, a lack of coagulopathy, and reduced or absent serum markers of inflammation and/or hepatic/renal function. Surprisingly, two surviving animals from the 100 and 50 PFU cohorts developed transient low-level viremia in the absence of other clinical signs of disease. Conversely, all animals in the 10 PFU cohort remained disease free and survived to the study endpoint.

Conclusions
Our observations highlight the susceptibility of NHPs, and by extension, likely humans, to relatively low doses of EBOV via the oral route. As this route of infection is likely a common portal of entry for filoviruses during outbreaks, the data presented here add to our understanding of the pathogenesis and host-response to infection under conditions mimicking real-world scenarios.​

https://academic.oup.com/jid/advance-article-abstract/doi/10.1093/infdis/jiad225/7205316
 
Back
Top